Plasma microRNA signature is associated with risk stratification in prostate cancer patients

Standard

Plasma microRNA signature is associated with risk stratification in prostate cancer patients. / Al-Qatati, Abeer; Akrong, Christine; Stevic, Ines; Pantel, Klaus; Awe, Julius; Saranchuk, Jeff; Drachenberg, Darrel; Mai, Sabine; Schwarzenbach, Heidi.

in: INT J CANCER, Jahrgang 141, Nr. 6, 15.09.2017, S. 1231-1239.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Al-Qatati, A, Akrong, C, Stevic, I, Pantel, K, Awe, J, Saranchuk, J, Drachenberg, D, Mai, S & Schwarzenbach, H 2017, 'Plasma microRNA signature is associated with risk stratification in prostate cancer patients', INT J CANCER, Jg. 141, Nr. 6, S. 1231-1239. https://doi.org/10.1002/ijc.30815

APA

Al-Qatati, A., Akrong, C., Stevic, I., Pantel, K., Awe, J., Saranchuk, J., Drachenberg, D., Mai, S., & Schwarzenbach, H. (2017). Plasma microRNA signature is associated with risk stratification in prostate cancer patients. INT J CANCER, 141(6), 1231-1239. https://doi.org/10.1002/ijc.30815

Vancouver

Bibtex

@article{bf63c38b55de42fb97d49baedce39709,
title = "Plasma microRNA signature is associated with risk stratification in prostate cancer patients",
abstract = "The aim of this study was to establish a unique expression profile of circulating cell-free microRNAs (miRNAs) capable of differentiating between prostate cancer (PCa) patients with high-risk and intermediate-risk Gleason scores. MiRNA expression profiles were determined in plasma samples from 79 treatment-na{\"i}ve PCa patients, 1-2 follow-up samples after radical prostatectomy (RP) from 51 out of the 79 PCa patients, and 33 healthy men, using a quantitative real-time PCR-based array containing 48 selected miRNAs. We identified 27 up- and 2 downregulated plasma miRNAs in PCa patients compared with healthy men. Most of the upregulated miRNA levels were also associated with increasing PSA levels and Gleason scores. Particularly, the levels of miR-16 (p = 0.002), miR-148a (p = 0.006) and miR-195 (p = 0.006) significantly correlated with high-risk Gleason scores, whereby miR-148a (p = 0.003) was also significantly associated with increasing PSA values. The high miRNA levels before RP remained increased in the postsurgical plasma samples. Our findings show a network of deregulated plasma miRNAs. In particular, miR-16, miR-148a and miR-195 are involved in the regulation of the PI3K/Akt signaling pathway. These miRNAs may be promising therapeutic targets for high-risk PCa stratification.",
keywords = "Journal Article",
author = "Abeer Al-Qatati and Christine Akrong and Ines Stevic and Klaus Pantel and Julius Awe and Jeff Saranchuk and Darrel Drachenberg and Sabine Mai and Heidi Schwarzenbach",
note = "{\textcopyright} 2017 UICC.",
year = "2017",
month = sep,
day = "15",
doi = "10.1002/ijc.30815",
language = "English",
volume = "141",
pages = "1231--1239",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Plasma microRNA signature is associated with risk stratification in prostate cancer patients

AU - Al-Qatati, Abeer

AU - Akrong, Christine

AU - Stevic, Ines

AU - Pantel, Klaus

AU - Awe, Julius

AU - Saranchuk, Jeff

AU - Drachenberg, Darrel

AU - Mai, Sabine

AU - Schwarzenbach, Heidi

N1 - © 2017 UICC.

PY - 2017/9/15

Y1 - 2017/9/15

N2 - The aim of this study was to establish a unique expression profile of circulating cell-free microRNAs (miRNAs) capable of differentiating between prostate cancer (PCa) patients with high-risk and intermediate-risk Gleason scores. MiRNA expression profiles were determined in plasma samples from 79 treatment-naïve PCa patients, 1-2 follow-up samples after radical prostatectomy (RP) from 51 out of the 79 PCa patients, and 33 healthy men, using a quantitative real-time PCR-based array containing 48 selected miRNAs. We identified 27 up- and 2 downregulated plasma miRNAs in PCa patients compared with healthy men. Most of the upregulated miRNA levels were also associated with increasing PSA levels and Gleason scores. Particularly, the levels of miR-16 (p = 0.002), miR-148a (p = 0.006) and miR-195 (p = 0.006) significantly correlated with high-risk Gleason scores, whereby miR-148a (p = 0.003) was also significantly associated with increasing PSA values. The high miRNA levels before RP remained increased in the postsurgical plasma samples. Our findings show a network of deregulated plasma miRNAs. In particular, miR-16, miR-148a and miR-195 are involved in the regulation of the PI3K/Akt signaling pathway. These miRNAs may be promising therapeutic targets for high-risk PCa stratification.

AB - The aim of this study was to establish a unique expression profile of circulating cell-free microRNAs (miRNAs) capable of differentiating between prostate cancer (PCa) patients with high-risk and intermediate-risk Gleason scores. MiRNA expression profiles were determined in plasma samples from 79 treatment-naïve PCa patients, 1-2 follow-up samples after radical prostatectomy (RP) from 51 out of the 79 PCa patients, and 33 healthy men, using a quantitative real-time PCR-based array containing 48 selected miRNAs. We identified 27 up- and 2 downregulated plasma miRNAs in PCa patients compared with healthy men. Most of the upregulated miRNA levels were also associated with increasing PSA levels and Gleason scores. Particularly, the levels of miR-16 (p = 0.002), miR-148a (p = 0.006) and miR-195 (p = 0.006) significantly correlated with high-risk Gleason scores, whereby miR-148a (p = 0.003) was also significantly associated with increasing PSA values. The high miRNA levels before RP remained increased in the postsurgical plasma samples. Our findings show a network of deregulated plasma miRNAs. In particular, miR-16, miR-148a and miR-195 are involved in the regulation of the PI3K/Akt signaling pathway. These miRNAs may be promising therapeutic targets for high-risk PCa stratification.

KW - Journal Article

U2 - 10.1002/ijc.30815

DO - 10.1002/ijc.30815

M3 - SCORING: Journal article

C2 - 28571116

VL - 141

SP - 1231

EP - 1239

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 6

ER -